奥西洛司他在库欣综合征中的真实世界有效性与安全性:回顾性IV期研究
该多中心回顾性IV期研究纳入意大利11个内分泌中心的100例库欣综合征患者,评估奥西洛司他的真实世界有效性与安全性。结果显示81%患者末次观察时UFC正常,92%至少一次正常,不良反应发生率29%,以肾上腺功能不全最常见(20%)。奥西洛司他有效且耐受性良好,可实现快速持久的激素控制并改善代谢、心血管、临床和生活质量指标。
要点
- 81%患者末次观察时UFC正常,92%至少一次正常。
- 80例达正常者首次正常化平均时间92.1天,平均剂量7.2 mg/日。
- 不良反应29%,多为轻中度,肾上腺功能不全最常见(20%)。
核心结论
- 奥西洛司他在常规临床实践中有效且总体耐受良好,是库欣综合征管理的 valuable 治疗选择。
- 可实现快速持久的激素控制,并显著改善代谢、心血管、临床和生活质量指标。
研究设计与样本
- 多中心、回顾性、IV期研究,纳入意大利11个内分泌转诊中心的100例库欣综合征患者。
- 患者构成:74%垂体性,16%肾上腺性,10%异位性。
主要发现
- 81%患者末次观察时UFC≤ULN,92%在研究期间至少一次UFC≤ULN。
- 排除12例基线UFC正常者后,78.4%末次观察时UFC正常,90.9%至少一次正常。
- 80例达正常者首次UFC正常化时间平均±SD为92.1±86.3天(中位数67.5,范围8-455),对应奥西洛司他剂量平均±SD为7.2±6.8 mg/日(中位数5,范围1-40)。
- 深夜唾液皮质醇和晨血清皮质醇显著降低;人体测量参数、血压、糖代谢、临床体征和生活质量均有改善。
- 不良反应发生率29%,多为轻中度;肾上腺功能不全最常见,报告于20%患者。
关键数值与推荐
- 主要终点:末次观察时UFC≤ULN的患者百分比。
- 次要终点包括生化与激素控制、临床结局、生活质量、不良反应。
- 激素控制与安全性特征在不同库欣综合征病因间一致。
临床怎么用
- 奥西洛司他可考虑用于库欣综合征的药物治疗,以实现快速持久的激素控制。
- 治疗中需监测肾上腺功能不全等不良反应,多数为轻中度。
- 不同病因(垂体、肾上腺、异位)的库欣综合征患者均可获益。
局限性
- 回顾性研究设计。
- 样本量100例。
- 来自意大利11个转诊中心,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Osilodrostat has demonstrated efficacy in clinical trials for Cushing's syndrome (CS). Real-world data remain limited. OBJECTIVE: To assess real-world effectiveness and safety of osilodrostat in a large cohort of CS patients. DESIGN&SETTING: Multicenter, retrospective, phase IV-study across 11 Italian endocrine referral centers. PATIENTS: 100 CS patients [74% pituitary, 16% adrenal, 10% ectopic]. MAIN OUTCOME MEASURES: Primary endpoint was the percentage of patients with UFC≤ULN at their last observation. Secondary endpoints included biochemical and hormonal control, clinical outcomes, QoL, AEs. RESULTS: 81% of patients had normal UFC levels at last observation, 92% at least once within study period. Excluding 12 patients with normal baseline UFC levels, 78.4% of patients had normal UFC levels at their last observation, whereas 90.9% at least once within the study period.The mean±SD (median,range) time to the first normalization of UFC levels, in the 80 patients who achieved normalization, was 92.1±86.3 (67.5,8-455) days, at a mean± SD (median,range) osilodrostat dose of 7.2±6.8 (5,1-40) mg/day.Significant reductions in late-night salivary cortisol and morning serum cortisol levels were observed. Improvements were noted in anthropometric parameters, blood pressure, glucose metabolism, clinical signs, and QoL. AEs occurred in 29% of patients, mostly mild-to-moderate; adrenal insufficiency was the most common AE reported in 20% of patients. Hormonal control and safety profiles were consistent across CS etiologies. CONCLUSIONS: Osilodrostat is effective, generally well tolerated in routine clinical practice, representing a valuable therapy for CS management, able to achieve rapid and sustained hormonal control, significant metabolic, cardiovascular, clinical and QoL improvements with a well-tolerated safety profile.
引用
- Pivonello R, Simeoli C, Di Paola N, et al. Real-World Effectiveness and Safety of Osilodrostat in Cushing's Syndrome: A Retrospective Phase IV Study. J Clin Endocrinol Metab. 2026. PMID: 42517566. doi:10.1210/clinem/dgag297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。